Nearly 40% of patients who received chimeric antigen receptor T-cell therapy required hospitalization for disease- or treatment-related reasons in the year after infusion, results of a research letter in JAMA Oncology showed.
More than one in five CAR-T recipients required at least one ED visit in the year after treatment, leading to investigators to conclude that certain high-risk subgroups may require intensive health care utilization after therapy.
The relative novelty of CAR T-cell therapy means most outcomes studies have been conducted in clinical trial settings. This may not always be an